Current Neurology and Neuroscience Reports

, Volume 9, Issue 5, pp 384–389

Current pharmacologic testing for horner syndrome


DOI: 10.1007/s11910-009-0056-z

Cite this article as:
Mughal, M. & Longmuir, R. Curr Neurol Neurosci Rep (2009) 9: 384. doi:10.1007/s11910-009-0056-z


First described in 1727, Horner syndrome occurs from injury to one of the three neurons in the oculo-sympathetic pathway. Its presence can be confirmed with pharmacologic testing, traditionally including cocaine testing with hydroxyamphetamine localization. More recently, apraclonidine testing has become a viable alternative in some practices. Concern has been raised regarding the possibility of false-negative results with apraclonidine testing as well as the safety of its use in young children.

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual SciencesThe University of Iowa Hospitals and ClinicsIowa CityUSA

Personalised recommendations